Cargando…

Efficacy and safety of a new intravenous immunoglobulin (Panzyga(®)) in chronic immune thrombocytopenia

OBJECTIVES: To assess the efficacy and safety of intravenous immunoglobulin (IVIG) 10% (Panzyga(®)), a novel human normal IVIG 10%, in patients with chronic immune thrombocytopenia (ITP). BACKGROUND: First‐line treatment options in ITP include IVIGs. METHODS: In this prospective, open‐label, non‐con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arbach, O., Taumberger, A. B., Wietek, S., Cervinek, L., Salama, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850321/ https://www.ncbi.nlm.nih.gov/pubmed/30687970 http://dx.doi.org/10.1111/tme.12573

Ejemplares similares

Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study
por: Borte, Michael, et al.
Publicado: (2017)

Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia
por: Rodeghiero, Francesco, et al.
Publicado: (2018)

Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP)
por: Hong, Junshik, et al.
Publicado: (2018)

PB2637: OUR EXPERIENCE WITH AVATROMBOPAG TREATMENT IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Cervinek, Libor
Publicado: (2023)

The safety and efficacy of intravenous immunoglobulin in autoimmune encephalitis
por: Lee, Soon‐Tae, et al.
Publicado: (2022)

Antiplatelet Antibodies Do Not Predict the Response to Intravenous Immunoglobulins during Immune Thrombocytopenia
por: Rogier, Thomas, et al.
Publicado: (2020)

Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia
por: Kaur, Manraj N., et al.
Publicado: (2022)

Isoagglutinin‐reduced immunoglobulin retains efficacy in mouse models of immune thrombocytopenia and rheumatoid arthritis and is less likely to cause intravenous immunoglobulin–associated hemolysis
por: Cen, Selena Y., et al.
Publicado: (2019)

Successful Use of Intravenous Immunoglobulins in an Obinutuzumab-related Acute Thrombocytopenia
por: Haage, Tobias R., et al.
Publicado: (2022)

Intravenous Immunoglobulin (IVIg) Utilization in Immune Thrombocytopenia (ITP): A Multi-Center, Retrospective Review
por: Hsia, Cyrus C., et al.
Publicado: (2015)

Secondary Immune Thrombocytopenia Associated With Asymptomatic COVID-19 Successfully Managed With Intravenous Immunoglobulin and Glucocorticoids
por: Ayesh, Hazem, et al.
Publicado: (2021)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
por: Scheuerlein, Philipp, et al.
Publicado: (2018)

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies
por: Perez, Elena E., et al.
Publicado: (2021)

Platelet count recovery after intravenous immunoglobulin predicts a favorable outcome in children with immune thrombocytopenia
por: Choi, Hyoung Soo, et al.
Publicado: (2016)

Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia
por: Janssens, Ann, et al.
Publicado: (2016)

Early Utilization of Intravenous Immunoglobulin in Heparin-Induced Thrombocytopenia for Limb Salvaging Purposes
por: Abu Kar, Sarah, et al.
Publicado: (2022)

Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia
por: Cheung, Eric, et al.
Publicado: (2009)

A serious thrombotic event in a patient with immune thrombocytopenia requiring intravenous immunoglobulin: a case report
por: Rungjirajittranon, Tarinee, et al.
Publicado: (2019)

Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2012)

Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia
por: Broome, Catherine M., et al.
Publicado: (2022)

Low-dose intravenous immunoglobulin for children with newly diagnosed immune thrombocytopenia: protocol of a systematic review and meta-analysis
por: Ren, Xiangge, et al.
Publicado: (2023)

Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2015)

Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2022)

Virus safety of intravenous immunoglobulin: Future challenges
por: Boschetti, Nicola, et al.
Publicado: (2005)

The Efficacy and Safety of High-Dose Intravenous Immunoglobulin in the Treatment of Kawasaki Disease: How Can We Predict Resistance to Intravenous Immunoglobulin Treatment of Kawasaki Disease?
por: Han, Ji Whan
Publicado: (2017)

Effect of intravenous immunoglobulin therapy on the prognosis of patients with severe fever with thrombocytopenia syndrome and neurological complications
por: Liu, Yun, et al.
Publicado: (2023)

Efficacy and safety of intravenous immunoglobulins for the treatment of viral encephalitis: a systematic literature review
por: Wagner, Judith N., et al.
Publicado: (2021)

Efficacy and safety of intravenous immunoglobulin for treating refractory livedoid vasculopathy: a systematic review
por: Gao, Yimeng, et al.
Publicado: (2022)

Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia
por: Vishnu, Prakash, et al.
Publicado: (2016)

Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenia: a meta-analysis
por: Guo, Jian-Chun, et al.
Publicado: (2017)

Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2023)

Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus
por: Pulanić, Dražen, et al.
Publicado: (2023)

Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
por: Cornblath, David R., et al.
Publicado: (2023)

Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease
por: Ma, Yongmei, et al.
Publicado: (2022)

Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia
por: Cines, Douglas B., et al.
Publicado: (2017)

The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia
por: Uzun, Günalp, et al.
Publicado: (2021)

N‐glycan profiling alterations of serum and immunoglobulin G in immune thrombocytopenia
por: Wang, Wei, et al.
Publicado: (2021)

Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy
por: Adrichem, Max E., et al.
Publicado: (2022)

Bleeding is associated with intravenous immunoglobulin and therapeutic plasma exchange use in heparin‐induced thrombocytopenia: A propensity matched analysis
por: Soares Ferreira Júnior, Alexandre, et al.
Publicado: (2021)

Retracted: Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease
por: Healthcare Engineering, Journal of
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7ghjjstpoa8puftd4gp820uvpn